Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 11/20 | 0.60 |
| ▸ | DCUN1D1 | Q96GG9 | 11/20 | 0.60 |
| ▸ | FAAH | O00519 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15387772 | 0.83 | LMNA (0.57) | UBE2MDCUN1D1FAAHLMNAMAPT | |
| SCHEMBL11563630 | 0.81 | UBE2M (0.61) | UBE2MDCUN1D1FAAHLMNAMAPT | |
| SCHEMBL10500798 | 0.78 | LMNA (0.60) | DCUN1D1FAAHLMNAMAPTSMN1; SMN2 | |
| SCHEMBL11561860 | 0.78 | UBE2M (0.55) | UBE2MDCUN1D1FAAHLMNAMAPT | |
| SCHEMBL11566812 | 0.77 | UBE2M (0.57) | UBE2MDCUN1D1FAAHLMNAMAPT | |
| SCHEMBL11889046 | 0.76 | CYP2D6 (0.58) | ALDH1A1 | |
| SCHEMBL11569157 | 0.75 | UBE2M (0.54) | UBE2MDCUN1D1FAAHLMNAMAPT | |
| SCHEMBL18640301 | 0.75 | DCUN1D1 (1.00) | UBE2MDCUN1D1ALDH1A1 | |
| SCHEMBL2808157 | 0.75 | OPRL1 (0.56) | UBE2MDCUN1D1FAAHLMNAKDM4E | |
| SCHEMBL3895076 | 0.75 | TACR3 (0.57) | UBE2MDCUN1D1FAAHLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028515-A1 | NEW PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-02-03 | — | — | US | claimed |
| WO-2011012602-A1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-03 | — | — | WO | claimed |
| WO-2011012602-A1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-03 | — | — | WO | disclosed |
| EP-0121972-B1 | N-ARYL-ALPHA-AMINO-CARBOXAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028515-A1 | NEW PIPERIDINE DERIVATIVES | ADRA1D, ADORA1, H1-0 | UBE2M 4157/4885DCUN1D1 2524/4885FAAH 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.